

Taro-Zoledronic Acid (2020-03-30)

Report a Concern
(<http://www.healthycanadians.gc.ca/report-signalez/index-eng.php>)

Starting date:	March 30, 2020
Type of communication:	Drug Recall
Subcategory:	Drugs
Hazard classification:	Type I
Source of recall:	Health Canada
Issue:	Product Safety
Audience:	General Public, Healthcare Professionals, Hospitals
Identification number:	RA-72683

Last updated: 2020-04-02

Summary

- **Product:** Taro-Zoledronic Acid 5 mg/100 mL solution

- [Reason](#)
- [Depth of distribution](#)
- [Affected products](#)
- [Related AWRs](#)

Reason

The recall lots may contain particulate matter.

Depth of distribution

End users

Affected products

Taro-Zoledronic Acid 5 mg/100 mL solution

DIN, NPN, DIN-HIM

DIN 02415100

Dosage form

Solution

Strength

Zoledronic acid monohydrate 5 mg/100 mL

Lot or serial number

JKT1520A, JKT1580A, JKT1581A, JKT1642A, JKT1643A


Companies

Recalling Firm	Taro Pharmaceuticals Inc. 130 East Drive Brampton L6T 1C1
-----------------------	--

Ontario
CANADA

Marketing Authorization Holder Taro Pharmaceuticals Inc.
130 East Drive
Brampton
L6T 1C1
Ontario
CANADA

Related AWRs

	<u>Certain Lots of Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled due to potential presence of particulate matter (/recall-alert-rappel-avis/hc-sc/2020/72673a-eng.php).</u>	Advisory
2020-03-31 Health products		

Date modified: 2020-04-02